1093.HK लाइव सिग्नल्स | Getagraph.com के साथ लाभ को अधिकतम करें

Live Chart Being Loaded With Signals

Commentary (3 May 2024 @ 13:38):

Stats
आज की मात्रा	39.72M
औसत मात्रा	39.84M
बाजार मूल्य	80.28B
EPS	HKD0 ( 2024-03-19 )
अगली कमाई की तारीख	( HKD0.150 ) 2024-05-22
Last Dividend	HKD0.140 ( 2023-09-07 )
Next Dividend	HKD0 ( N/A )
P/E	12.75
ATR14	HKD0.00900 (0.13%)

मात्रा सहसंबंध

लंबा: -0.04 (neutral)

छोटा: -0.33 (neutral)

Signal:(57.559) Neutral

CSPC Pharmaceutical Group सहसंबंध

10 सबसे अधिक सकारात्मक सहसंबंध

10 सबसे अधिक नकारात्मक सहसंबंध

क्या आप जानते हैं?

कोरलेशन एक सांख्यिकीय माप है जो दो चरों के बीच संबंध का वर्णन करता है। यह -1 से 1 तक का होता है, जहाँ -1 एक पूर्ण नकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा कम होता है), 1 एक पूर्ण सकारात्मक कोरलेशन को दर्शाता है (जैसे ही एक चर बढ़ता है, दूसरा भी बढ़ता है) और 0 कोई कोरलेशन नहीं होता है (चरों के बीच कोई संबंध नहीं है)।

कोरलेशन किसी भी दो चरों के बीच संबंध का विश्लेषण करने के लिए इस्तेमाल किया जा सकता है, न कि केवल स्टॉक में। यह वित्तीय, अर्थशास्त्र, मनोविज्ञान और अन्य क्षेत्रों में आमतौर पर उपयोग किया जाता है।

CSPC Pharmaceutical Group सहसंबंध - मुद्रा/वस्त्र

0.75
( moderate )

0.72
( moderate )

0.00
( neutral )

0.62
( weak )

-0.70
( moderate negative )

CSPC Pharmaceutical Group वित्तीय

Annual	2023
राजस्व:	HKD34.75B
सकल लाभ:	HKD24.51B (70.51 %)
EPS:	HKD0.550

FY	2023
राजस्व:	HKD34.75B
सकल लाभ:	HKD24.51B (70.51 %)
EPS:	HKD0.550

FY	2022
राजस्व:	HKD35.98B
सकल लाभ:	HKD25.88B (71.94 %)
EPS:	HKD0.590

FY	2021
राजस्व:	HKD27.87B
सकल लाभ:	HKD21.14B (75.84 %)
EPS:	HKD0.470

Financial Reports:

No articles found.

CSPC Pharmaceutical Group Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
HKD0.100 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0.110 (N/A)	HKD0.140 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)	HKD0 (N/A)

CSPC Pharmaceutical Group Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 5.59 - Stable (11.71%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	HKD0.0365	2003-08-28
Last Dividend	HKD0.140	2023-09-07
Next Dividend	HKD0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	21	--
Total Paid Out	HKD1.673	--
Avg. Dividend % Per Year	0.00%	--
Score	3.25	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	5.59
Div. Directional Score	8.48	--

Next Divdend (Est)
(2024-09-03)

HKD0.150 Estimate 11.17 %

Dividend Stability

0.45 Below Average

Dividend Score

3.25

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for HKSE

Symbol	Title	Last dividend	Frequency	Yearly Dividend
2380.HK	Ex Dividend Junior	2023-06-12	Annually	0.00%
1359.HK	Ex Dividend Junior	2023-06-26	Annually	0.00%
0400.HK	Ex Dividend Junior	2023-06-13	Sporadic	0.00%
6811.HK	Ex Dividend Knight	2023-10-05	Semi-Annually	0.00%
1908.HK	Ex Dividend Junior	2023-06-01	Sporadic	0.00%
0941.HK	Ex Dividend Knight	2023-09-01	Semi-Annually	0.00%
0057.HK	Ex Dividend Knight	2023-09-01	Semi-Annually	0.00%
2899.HK	Ex Dividend Knight	2023-05-30	Annually	0.00%
1508.HK	Ex Dividend Junior	2023-06-29	Annually	0.00%
0553.HK	Ex Dividend Junior	2023-07-03	Annually	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.189	1.500	6.23	9.34	[0 - 0.5]
returnOnAssetsTTM	0.150	1.200	5.01	6.01	[0 - 0.3]
returnOnEquityTTM	0.224	1.500	8.62	10.00	[0.1 - 1]
payoutRatioTTM	0.533	-1.000	4.67	-4.67	[0 - 1]
currentRatioTTM	2.63	0.800	1.867	1.494	[1 - 3]
quickRatioTTM	2.27	0.800	1.336	1.069	[0.8 - 2.5]
cashRatioTTM	1.180	1.500	4.56	6.83	[0.2 - 2]
debtRatioTTM	0.0151	-1.500	9.75	-10.00	[0 - 0.6]
interestCoverageTTM	362.23	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	0.701	2.00	9.77	10.00	[0 - 30]
freeCashFlowPerShareTTM	0.369	2.00	9.82	10.00	[0 - 20]
debtEquityRatioTTM	0.0210	-1.500	9.92	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.707	1.000	1.551	1.551	[0.2 - 0.8]
operatingProfitMarginTTM	0.232	1.000	7.36	7.36	[0.1 - 0.6]
cashFlowToDebtRatioTTM	10.82	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.794	0.800	8.04	6.43	[0.5 - 2]
Total Score				11.38

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	10.49	1.000	9.04	0	[1 - 100]
returnOnEquityTTM	0.224	2.50	9.11	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	0.369	2.00	9.88	10.00	[0 - 30]
dividendYielPercentageTTM	3.70	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	0.701	2.00	9.77	10.00	[0 - 30]
payoutRatioTTM	0.533	1.500	4.67	-4.67	[0 - 1]
pegRatioTTM	-0.257	1.500	-5.04	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.205	1.000	7.37	0	[0.1 - 0.5]
Total Score				5.59

CSPC Pharmaceutical Group

CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People's Republic of China, other Asian regions, the Americas, Europe, and internationally. The company operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. It provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson's disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; and Keaili for breast cancer. The company also offers Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; Xuanning for hypertension; Encun to prevent atherosclerotic thrombosis events; Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; and Gaoshunsong for arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursuitis, tenosynovitis, acute gout, dysmenorrhea, toothache and postoperative pain, low back pain, sprain, strain, and other soft tissue injuries. In addition, it provides Debixin for various ulcer; Qimaite for acute and chronic pains; antibiotics, vitamin C, and caffeine APIs; functional food and glucose products; and healthcare services. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People's Republic of China.